ClinicalTrials.gg
CompletedNCT03347903Updated Nov 21, 2017

Prevalence and Clinical Characteristics of Patients With Jackhammer Esophagus and Symptoms of Gastroesophageal Reflux Disease

An observational study in Esophageal Motility Disorders, sponsored by Medical University of Vienna. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-11-21.

Sponsored by Medical University of Vienna · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
37
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Gastroesophageal reflux disease (GERD) is involved in the development of esophageal motility disorders like Jackhammer esophagus (JE), a novel hypercontractile condition that was associated with progression to achalasia and limited outcomes following surgical anti-reflux therapy.

This trial was designed to assess the prevalence and characteristics of JE in patients with typical symptoms of GERD and responsiveness to PPI therapy.

Read the detailed description

Jackhammer esophagus is a novel hypercontractile esophageal disorder. The investigators assess the prevalence and clinical characteristics of patients diagnosed with this disorder out of a collective of patients that are referred with symptoms of gastroesphageal reflux disease and respond to PPI. This is an observational trial.

02

Conditions studied

  • Esophageal Motility Disorders

Keywords

  • esophagus
  • motility
03

In context

Esophageal Motility Disorders

37 studies on the registry are indexed under Esophageal Motility Disorders; 11 are open to participants now.

This study's enrollment of 37 is below the median of 55 across 14 observational studies indexed under Esophageal Motility Disorders.

Browse Esophageal Motility Disorders studies →

Lead sponsor

Medical University of Vienna is the lead sponsor of 1,109 studies on the registry; 184 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

All patients that are referred to our center undergo esophageal high-resolution manometry and ambulatory pH monitoring for screening of gastroesophageal reflux disease and motility disorders. We assess the data that are prospectively obtained. Patients do not have to undergo any interventions.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with symptoms of gastroesophageal reflux disease and diagnosis of Jackhammer esophagus

Exclusion criteria

Exclusion Criteria:

  • patients not willing to participate data or undergo screening for gastroesophageal reflux disease
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
37 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Prevalence of Jackhammer esophagus in patients referred with symptoms of gastroesophageal reflux disease

    All patients that are referred to our center with symptoms of gastroesophageal reflux disease routinely undergo high-resolution manometry. We assess how many patients are diagnosed with Jackhammer esophagus

    Time frame: January 2014- May 2017

Secondary outcomes

  1. Symptom perception

    We assess which symptoms are perceived by the patients diagnosed with Jackhammer esophagus. All data are observed during an interview at the high-resolution manometry

    Time frame: January 2014- May 2017

  2. Prevalence of gastroesophageal reflux disease in patients with Jackhammer esophagus

    All patients that are referred to our center are evaluated for gastroesophageal reflux disease. We assess the prevalence of gastroesophageal reflux disease in patients with Jackhammer esophagus diagnosed by ambulatory pH monitoring.

    Time frame: Januar 2014- May 2017

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Kristo I, Schwameis K, Maschke S, Kainz A, Rieder E, Paireder M, Jomrich G, Schoppmann SF. Phenotypes of Jackhammer esophagus in patients with typical symptoms of gastroesophageal reflux disease responsive to proton pump inhibitors. Sci Rep. 2018 Jul 2;8(1):9949. doi: 10.1038/s41598-018-27756-9. PubMed 29967357 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2014 to primary completion in May 2017, 40 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 15, 2017
First posted
Nov 20, 2017
StartActual
Jan 1, 2014
Primary completionActual
May 30, 2017
CompletionActual
May 30, 2017
Last update
Nov 21, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03347903
Responsible party
Dr. Ivan Kristo (Dr. med. univ., Medical University of Vienna) — Principal investigator
First posted
Nov 20, 2017
Start date
Jan 1, 2014
Primary completion
May 30, 2017
Completion
May 30, 2017
Last update
Nov 21, 2017

Study contacts

Sebastian Schoppmann, MD
principal investigator · Vice Chair of Department of General Surgery

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion